- Home
- NUVL
NUVL
Nuvalent Inc.
as 12-17-2024 4:00pm EST
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 6.7B | IPO Year: | 2021 |
| Target Price: | $112.60 | AVG Volume (30 days): | 350.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $61.80 - $113.51 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hack Andrew A. F. | NUVL | Director | Dec 11 '24 | Sell | $88.00 | 1,250,000 | $110,000,000.00 | 1,447,267 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Nov 29 '24 | Sell | $95.97 | 10,000 | $957,940.48 | 33,300 | |
| Shair Matthew | NUVL | Director | Nov 25 '24 | Sell | $96.60 | 2,000 | $192,442.86 | 222,522 | |
| Porter James Richard | NUVL | President and CEO | Nov 15 '24 | Sell | $88.47 | 27,000 | $2,374,478.68 | 188,113 | |
| Noci Darlene | NUVL | Chief Development Officer | Nov 1 '24 | Sell | $88.94 | 5,000 | $442,980.40 | 33,300 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Oct 31 '24 | Sell | $89.67 | 10,000 | $891,879.40 | 33,300 | |
| Shair Matthew | NUVL | Director | Oct 28 '24 | Sell | $92.23 | 2,000 | $183,467.56 | 222,522 | |
| Flynn James E | NUVL | Director10% Owner | Oct 22 '24 | Sell | $97.75 | 2,000,000 | $195,500,000.00 | 8,670,512 | |
| Porter James Richard | NUVL | President and CEO | Oct 15 '24 | Sell | $102.64 | 27,000 | $2,761,630.50 | 188,113 | |
| Noci Darlene | NUVL | Chief Development Officer | Oct 1 '24 | Sell | $102.37 | 5,000 | $508,718.22 | 33,300 |
Latest Nuvalent Inc. News
NUVL Breaking Stock News: Dive into NUVL Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
Nuvalent Appoints Grant Bogle to Board of Directors
PR Newswire
22 days ago
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
MT Newswires
a month ago
Nuvalent's Q3 Net Loss Widens
PR Newswire
a month ago
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
MT Newswires
a month ago
Nuvalent Insider Sold Shares Worth $442,980, According to a Recent SEC Filing
MT Newswires
2 months ago
UBS Initiates Nuvalent With Neutral Rating, $100 Price Target
MT Newswires
3 months ago
Nuvalent Insider Sold Shares Worth $508,718, According to a Recent SEC Filing
Zacks
3 months ago
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Compare NUVL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.